دورية أكاديمية
أعرض في EDS

Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series.

التفاصيل البيبلوغرافية
العنوان: Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series.
المؤلفون: Patricelli CJ; From the Families in Recovery (FIR) Unit, BC Women's Hospital and Health Centre, Vancouver, BC, Canada (CJP, SG, IJG, NC, KS, VP); Women's Health Research Institute, Vancouver, BC, Canada (CJP, JC, SG, IJG, KU, AA); Department of Family Practice, University of British Columbia, Vancouver, BC, Canada (CJP); University of British Columbia Faculty of Medicine, Vancouver BC, Canada (JC); Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada (AA); Department of Public Health and Social Policy, University of Victoria, Victoria, BC, Canada (KU)., Chai J, Gordon S, Gouin IJ, Carter N, Stewart K, Paquette V, Urbanoski K, Albert A
المصدر: Journal of addiction medicine [J Addict Med] 2023 Jul-Aug 01; Vol. 17 (4), pp. 431-438. Date of Electronic Publication: 2023 Feb 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: Netherlands NLM ID: 101306759 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1935-3227 (Electronic) Linking ISSN: 19320620 NLM ISO Abbreviation: J Addict Med Subsets: MEDLINE
أسماء مطبوعة: Publication: [Alphen aan den Rijn, the Netherlands] : Wolters Kluwer Health, Inc.
Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Analgesics, Opioid*/therapeutic use , Opioid-Related Disorders*/drug therapy, Pregnancy ; Female ; Humans ; Opiate Substitution Treatment ; Retrospective Studies ; Hydromorphone/therapeutic use
مستخلص: Objectives: Untreated opioid use disorder (OUD) in pregnancy may lead to adverse outcomes for the individual and fetus. Injectable opioid agonist therapy (iOAT) is the highest intensity treatment for severe refractory OUD currently available; however, research on perinatal administration is limited. We present the first known case series of 13 pregnant or postpartum participants who received intravenous hydromorphone while admitted to the Families in Recovery (FIR) unit, an in-patient perinatal stabilization unit in Canada.
Methods: Patients who received iOAT at FIR between 2019 and 2022 were invited to participate. Prospectively enrolled participants completed a self-report sociodemographics and exposures survey. Medical/social backgrounds of participants at admission, iOAT and other opioid agonist therapy administration, and health/social outcomes of mother and infant at discharge were collected on all participants via retrospective maternal and infant medical chart review.
Results: Participants initiated iOAT while pregnant (n = 5) or postpartum (n = 8) and received iOAT for 23 days on average. At discharge, 8 participants underwent planned transition to community with infant in their care and a discharge plan including outpatient prescriptions, housing arrangements, follow-up appointments, and supportive programming. All infants received oral morphine after delivery and were discharged in good health.
Conclusions: This is the first known case series of iOAT administration in the peripartum. The cases illustrate iOAT as an option that can achieve OUD stabilization in perinatal individuals to support patient engagement and retention in care.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine.)
References: Can J Psychiatry. 2018 May;63(5):322-328. (PMID: 29082774)
J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9. (PMID: 12924748)
Can J Public Health. 2020 Aug;111(4):606-609. (PMID: 32221867)
BMJ Case Rep. 2019 Aug 1;12(7):. (PMID: 31371332)
J Obstet Gynaecol Can. 2017 Mar;39(3):157-165. (PMID: 28343557)
Eur Addict Res. 2008;14(2):113-4. (PMID: 18334822)
Addict Behav. 2019 Nov;98:106030. (PMID: 31301645)
J Perianesth Nurs. 2009 Jun;24(3):186-90. (PMID: 19500754)
J Addict Med. 2021 Sep-Oct 01;15(5):435-438. (PMID: 33234803)
CMAJ Open. 2021 Feb 23;9(1):E115-E124. (PMID: 33622764)
J Addict Med. 2023 Mar-Apr 01;17(2):222-226. (PMID: 36001061)
J Addict Med. 2023 May-Jun 01;17(3):e148-e155. (PMID: 37267166)
CMAJ Open. 2015 Jan 13;3(1):E55-61. (PMID: 25844370)
Pediatrics. 2021 Oct;148(4):. (PMID: 34479983)
المشرفين على المادة: 0 (Analgesics, Opioid)
Q812464R06 (Hydromorphone)
تواريخ الأحداث: Date Created: 20230814 Date Completed: 20231102 Latest Revision: 20231113
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10417207
DOI: 10.1097/ADM.0000000000001152
PMID: 37579103
قاعدة البيانات: MEDLINE
الوصف
تدمد:1935-3227
DOI:10.1097/ADM.0000000000001152